Dr. Gaudreau is a medical oncologist and hematologist whose research focuses on early-phase clinical trials, mechanisms of response and resistance to immunotherapy and innovative anti-cancer agents, and thoracic malignancies. He completed his training at the University of Montreal (MD, PhD), the University of Texas MD Anderson Cancer Center (doctoral research fellowship) and McGill University (post-doctoral research fellowship). Dr. Gaudreau joined the Canadian Clinical Trials Group (CCTG) in 2020 as a Senior Investigator for the Investigational New Drug Program and the Thoracic Oncology Disease Site Committee. He is also an Assistant Professor in the Department of Oncology at Queen’s University, and practices as a thoracic medical oncologist at the Kingston Health Sciences Centre.
Areas of expertise: early-phase clinical trials, translational research, immuno-oncology, lung cancer
Research interests: early-phase clinical trials, investigational new drugs, tumor drug resistance, mechanisms of resistance to immunotherapy, novel immunotherapy combination strategies, lung cancer
For a full list of publications please visit Pub Med